Comparison
Alagebrium vs Rapamycin
AGE crosslink breaker vs. mTORC1 inhibitor — targeted reversal versus systemic prevention.
Alagebrium
AGE Crosslink Breaker
Longevityt½ ~6–12 hours (estimated)
Rapamycin
mTOR Inhibitor
Longevityt½ ~62 hours (range 46–78h)
Effectiveness Profile
Alagebrium
Rapamycin
At a Glance
| Alagebrium | Rapamycin | |
|---|---|---|
| Type | Longevity | Longevity |
| Legal status | Research | Rx-Only |
| Half-life | ~6–12 hours (estimated) | ~62 hours (range 46–78h) |
| Preferred route | Oral | Oral |
| Dose frequency | once-daily | weekly |
| Beginner dose | 100–200 mg | 2–3 mg |
| Intermediate dose | 200–200 mg | 4–6 mg |
| Advanced dose | 200–420 mg | 6–8 mg |
| Cycle length | 12–36 wks | 8–52 wks |
| Bioavailability | — | 15% |
| Time to peak | — | 1.5h |
| Active duration | 12h | 168h |
| Storage | Sealed, dry, room temperature or cooler; protect from humidity (thiazolium ring is hydrolytically labile) | Room temperature (15–25°C); protect from light |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
Alagebrium wins for targeted reversal of advanced glycation end-product (AGE) crosslinks in stiff, already-damaged vasculature, clean side-effect profile at documented doses, and direct impact on arterial compliance in older subjects. Rapamycin wins for broad, systemic longevity support with robust lifespan data, unique mTORC1-driven healthspan benefits, autophagy induction, and proven effects in both healthy and aged phenotypes. Rapamycin protocols carry more direct evidence for median and maximum lifespan extension.
Pick A or B?
Pick Alagebrium if:
- The research focus is on reversing arterial stiffness or diastolic dysfunction in older or long-cycle-exposed subjects.
- The goal is direct AGE crosslink cleavage for vascular or dermal endpoints.
- Clean tolerability and a side-effect-minimal profile are top priorities.
- Studies require a compound that works downstream of hyperglycemia, not just a preventive.
- Topical crosslink reversal in skin tissue models is a target.
Pick Rapamycin if:
- The research aim is systemic lifespan/healthspan extension—especially with intervention beginning mid- or late-life.
- mTORC1 inhibition, autophagy upregulation, or immune rejuvenation are mechanistic endpoints.
- Weekly pulse protocols (minimum day-to-day intervention) are preferred.
- Proven impact across a wider array of aging biomarkers is required.
- The protocol involves stacking with GLP-1, metformin, or other "three horsemen" approaches.
This comparison is presented for informational and educational purposes only. The compounds described may be research chemicals, prescription-only, or regulated substances in your jurisdiction. Consult a qualified medical professional before using any compound. This is not medical advice.